Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO CEO: getting payback from investing in investors

This article was originally published in Scrip

Executive Summary

Investors in the life sciences are patient, by necessity perhaps rather than by inclination. And yet they still want returns – certainly faster than biotechnology companies have delivered them. But what happens when a company suddenly gets a big win, through a product approval or a big upfront payments or milestones on a deal? Should it reinvest in what it sees as the growth engine of the company or should it dispense value to its supportive shareholders through dividends or other rights?

Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts